<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136656</url>
  </required_header>
  <id_info>
    <org_study_id>P040422</org_study_id>
    <secondary_id>AOM 04 105</secondary_id>
    <nct_id>NCT00136656</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old</brief_title>
  <official_title>Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the equivalence of the therapeutic efficacy of
      cefixime by mouth (PO) 10 days (d) and ceftriaxone intravenous route(IV) 4d followed by
      cefixime PO 6d on renal scars 6 months after a first acute pyelonephritis episode.

      The investigators hypothesize that treatment with cefixime PO will allow no more renal scars
      than intravenous route (IV) treatment of pyelonephritis in infants and children less than 3
      years old, 6 months after the first episode. If it is true, treatment will no longer need
      hospitalisation and the advantages for children, families and the health system will be very
      important.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Guidelines for treatment of acute pyelonephritis in infants and children are different from
      one country to another. The main question is the incidence of renal scars.

      intravenous route (IV) treatment is supposed to give the best results, but no previous study
      has ever given the incidence of renal scars after PO treatment.

      This multicenter, randomised trial is an equivalence study of PO and intravenous route (IV)
      treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal scars on dimercaptosuccinic acid (DMSA) renal scan at 6 months</measure>
    <time_frame>between six and eight months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to get apyrexia</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urologic abnormalities on cystourethrography done during the first month after the infection</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefixime antibiotic treatment by oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotic</intervention_name>
    <description>cephalosporine by oral route : cefixime</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotics</intervention_name>
    <description>cephalosporine : ceftriaxone by intra venous route and cefixime by oral route</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants and children more than 1 month old and less than 3 years old

          -  First episode of acute pyelonephritis with gram negative strains

          -  Fever more than 38.5°C

          -  Procalcitonin (PCT) value &gt; 0.5 ng/ml

          -  Urine obtained by transurethral bladder catheterization, suprapubic aspiration or
             midstream collection

          -  Urine exam: more than 100.000 leukocytes and gram negative strains +

          -  Normal hemodynamic exam

          -  Normal renal ultrasonography

          -  Positive DMSA renal scan for pyelonephritis during the first week after diagnosis

          -  Parental informed consent

        Exclusion Criteria:

          -  Newborn

          -  Children more than 3 years old

          -  Past urine infection

          -  Septic hemodynamic abnormalities

          -  Obstructive uropathy and any renal ultrasonography abnormalities

          -  Allergy to cefixime or ceftriaxone

          -  Antibiotic during the five previous days

          -  Gastrointestinal abnormalities able to interfere with antibiotic intake or absorption

          -  Absence of parental consent

          -  Social familial difficulties
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHERON GERARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker Enfants Malades Assistance Publique Hôpitaux de Paris - René Descartes University Paris 5</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHEVALLIER BERTRAND, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ambroise Paré Hospital, Assistance Publique Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GAJDOS VINCENT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Antoine Béclère Hospital Assistance Publique Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LABRUNE PHILIPPE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Antoine Béclère Hospital Assistance Publique Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GRIMPREL EMMANUEL, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trousseau Hospital AP HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DESCHENES GEORGES, MD</last_name>
    <role>Study Chair</role>
    <affiliation>TROUSSEAU HOSPITAL AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SERGENT ALINE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>TROUSSEAU HOSPITAL AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VAYLET CLAIRE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>TROUSSEAU HOSPITAL AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BADER MEUNIER BRIGITTE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BICETRE HOSPITAL AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GUIGONIS VINCENT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>DUPUYTREN HOSPITAL CHU LIMOGES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de Bicetre</name>
      <address>
        <city>Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Pare</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Andre Mignot</name>
      <address>
        <city>Versailles</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sannier N, Le Masne A, Sayegh N, Gaillard JL, Chéron G. Ambulatory management of acute pyelonephritis in children. Acta Paediatr. 2000 Mar;89(3):372-3.</citation>
    <PMID>10772296</PMID>
  </reference>
  <reference>
    <citation>Leroy S, Marc E, Adamsbaum C, Gendrel D, Bréart G, Chalumeau M. Prediction of vesicoureteral reflux after a first febrile urinary tract infection in children: validation of a clinical decision rule. Arch Dis Child. 2006 Mar;91(3):241-4. Epub 2005 May 12.</citation>
    <PMID>15890693</PMID>
  </reference>
  <reference>
    <citation>Leroy S, Adamsbaum C, Marc E, Moulin F, Raymond J, Gendrel D, Bréart G, Chalumeau M. Procalcitonin as a predictor of vesicoureteral reflux in children with a first febrile urinary tract infection. Pediatrics. 2005 Jun;115(6):e706-9. Epub 2005 May 2.</citation>
    <PMID>15867014</PMID>
  </reference>
  <reference>
    <citation>Marc E, Ménager C, Moulin F, Stos B, Chalumeau M, Guérin S, Lebon P, Brunet F, Raymond J, Gendrel D. [Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak]. Arch Pediatr. 2002 Apr;9(4):358-64. French.</citation>
    <PMID>11998420</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Thérèse NGOUE</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>infant</keyword>
  <keyword>children</keyword>
  <keyword>pyelonephritis</keyword>
  <keyword>Renal scars</keyword>
  <keyword>DMSA scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

